Description
Dihexa | Angiotensin IV Analogue — Research Grade
Dihexa (PNB-0408) is a brain-penetrant small molecule derived from angiotensin IV with high affinity for the AT4 receptor (IRAP, insulin-regulated aminopeptidase). It was developed at Washington State University and has been characterised as an exceptionally potent synaptogenic compound in preclinical models.
Mechanism of Action
- AT4/IRAP inhibition — binds and inhibits IRAP, increasing local concentration of endogenous neuropeptides including oxytocin and vasopressin at synaptic sites
- HGF/c-Met signalling — activates hepatocyte growth factor receptor (c-Met) in hippocampal neurons, a pathway critical for synaptogenesis
- Synapse formation — preclinical data report synaptogenic potency approximately 10 million-fold greater than BDNF in hippocampal neuron models
- BBB penetration — lipophilic structure allows oral bioavailability and CNS access in rodent models
Research Areas
Dihexa is studied in Alzheimer disease models, cognitive decline, traumatic brain injury, and synaptogenesis research. Its extreme potency in preclinical synaptogenesis assays makes it a high-interest compound in neuroplasticity research.
For Research Use Only. Rainbow Peptide supplies Dihexa exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. J. Banks –
Dihexa for our HGF/Met pathway and synaptogenesis research. Purity confirmed >99% by our HPLC. Synaptic density response in our neuronal culture model exceeded what we’d seen from previous suppliers. Outstanding COA.
E. Johanssen –
Third order of Dihexa for our cognitive enhancement research. Batch consistency is excellent. LC-MS confirms molecular weight and purity >99% each time. Dissolved cleanly in DMSO. Highly recommend.
P. Abara –
Dihexa performed as expected in our HGF receptor potentiation assay. Purity >98.5%. COA thorough. Arrived with cold pack. Will continue sourcing from Rainbow Peptide for our memory research program.